Pacira BioSciences, Inc. - PCRX STOCK NEWS

Pacira BioSciences (NASDAQ: PCRX) announced that the European Commission has granted marketing authorization for EXPAREL for managing post-operative pain in adults. This approval is based on four Phase 3 studies that showed EXPAREL significantly reduces pain and opioid consumption after surgery. The marketing authorization covers all EU member states, the UK, Iceland, Norway, and Liechtenstein, with a launch planned for late 2021. Since its U.S. launch in 2012, EXPAREL has been administered to over 7.5 million patients.

Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $40.7 million and iovera° at $1 million for October 2020. EXPAREL sales grew by 112% year-over-year, marking five consecutive months of growth. Despite challenges from the COVID-19 pandemic affecting elective surgeries, EXPAREL is increasingly used in various surgical procedures. The company plans to continue monthly sales reports to improve transparency regarding COVID-19's impact.

Pacira BioSciences (NASDAQ: PCRX) will present at the 2020 Jefferies Virtual London Healthcare Conference on November 17, 2020, at 2:05 PM GMT (9:05 AM ET). The presentation will be accessible via the company’s events page, with a replay available for two weeks afterward. Pacira is recognized for its commitment to non-opioid pain management solutions, notably through its long-acting local analgesic EXPAREL®, launched in 2012. The company focuses on reducing opioid reliance in healthcare.

Pacira BioSciences (Nasdaq: PCRX) reported a 12% increase in total revenues to $117.5 million for Q3 2020, driven by strong EXPAREL sales, which reached $113.7 million. The net income increased significantly to $130.1 million, aided by a $124.6 million income tax benefit. Operating expenses decreased to $99.9 million, while adjusted EBITDA rose to $34.2 million from $24.8 million a year prior. The company opened a new training facility to enhance pain management practices and reported preliminary September 2020 sales of $39.5 million for EXPAREL. A positive CHMP opinion for EXPAREL was also noted.

Pacira BioSciences, Inc. has launched the Pacira Innovation and Training Center of Tampa (PITT), aimed at enhancing clinician education in non-opioid pain management techniques. The facility features state-of-the-art technology, including ultrasound scanning stations and a large LCD presentation wall. Ongoing workshops will focus on iovera° training, promoting best practices in pain management. Pacira emphasizes the importance of training for improved patient outcomes, reflecting a commitment to shift procedures toward non-opioid solutions. This strategic initiative is expected to contribute to the growing field of regional anesthesia.

Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its third quarter financial results on October 29, 2020, before U.S. market opening. Following this, a live conference call and webcast will be held at 8:30 a.m. ET. Participants can join by dialing 1-877-845-0779 or 1-720-545-0035 (international), using passcode 5997369. Replay options will be available for one week. Pacira is known for its non-opioid pain management solutions, especially its long-acting analgesic, EXPAREL®, and the iovera⁰ cryoanalgesia device.

Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $113.7 million and iovera° at $2.7 million for Q3 2020. Sales for September were $39.5 million for EXPAREL and $1.1 million for iovera°. EXPAREL average daily sales exceeded prior year levels at 110% for September. The company is optimistic about future growth due to increased demand for EXPAREL in both elective and non-elective procedures. A new Innovation and Training Center in Tampa is set to enhance training for pain management techniques.

Pacira BioSciences (Nasdaq: PCRX) announced a positive opinion from the European Medicines Agency’s CHMP recommending marketing authorization for its pain management drug, EXPAREL, for postsurgical analgesia. This recommendation was supported by four pivotal studies highlighting EXPAREL's effectiveness in reducing pain scores and opioid use in various surgical settings. A final European Commission decision is expected in November 2020. This step aligns with Pacira's vision to lead in non-opioid pain management, with EXPAREL already utilized in over seven million patients in the U.S.

Pacira BioSciences (PCRX) and IPG have announced a partnership aimed at reducing postsurgical opioid prescriptions and lowering surgical costs across IPG's health plan network. The collaboration will see IPG reimbursing for EXPAREL®, a non-opioid pain management solution, to enhance surgical care quality and affordability. Both companies will create educational resources to optimize pain management practices, with Pacira emphasizing the benefits of non-opioid approaches for improved patient outcomes and satisfaction.